Pulse Biosciences IncNASDAQ PLSE Stock Report

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 142 full-time employees. The company went IPO on 2016-05-18. The firm provides CellFX System, which is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System includes a multi-use handpiece and a suite of single-patient use treatment tips ranging from approximately 1.5 square millimeter (mm2) to 10 mm2, enabling treatment of a variety of lesion sizes and depths. The treatment tips wirelessly connect to the CellFX System when plugged into the handpiece, allowing for the use of automated treatment settings based on the treatment tip used. The firm has commercialized its CellFX System into the procedure market as its commercial market. Powered by the Company’s Nano-Pulse Stimulation (NPS) technology, the CellFX System delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.